Wall Street brokerages forecast that Express Scripts Holding (NASDAQ:ESRX) will announce earnings per share (EPS) of $2.09 for the current quarter, Zacks reports. Twelve analysts have made estimates for Express Scripts’ earnings. The lowest EPS estimate is $2.03 and the highest is $2.14. Express Scripts reported earnings of $1.88 per share during the same quarter last year, which would indicate a positive year over year growth rate of 11.2%. The firm is expected to announce its next earnings results after the market closes on Tuesday, February 27th.
According to Zacks, analysts expect that Express Scripts will report full-year earnings of $7.03 per share for the current year, with EPS estimates ranging from $6.97 to $7.07. For the next fiscal year, analysts anticipate that the company will post earnings of $8.71 per share, with EPS estimates ranging from $7.60 to $9.40. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Express Scripts.
A number of research firms have recently issued reports on ESRX. Zacks Investment Research upgraded shares of Express Scripts from a “hold” rating to a “buy” rating and set a $82.00 target price for the company in a research note on Wednesday, February 14th. BidaskClub cut shares of Express Scripts from a “buy” rating to a “hold” rating in a research note on Wednesday, February 14th. Royal Bank of Canada upgraded shares of Express Scripts from a “sector perform” rating to an “outperform” rating and set a $68.00 target price for the company in a research note on Wednesday, January 31st. Sanford C. Bernstein cut shares of Express Scripts from a “market perform” rating to an “underperform” rating and raised their target price for the stock from $55.80 to $77.50 in a research note on Tuesday, January 30th. Finally, Mizuho set a $86.00 target price on shares of Express Scripts and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Express Scripts presently has an average rating of “Hold” and a consensus target price of $78.93.
In related news, VP Glen D. Stettin sold 3,449 shares of Express Scripts stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $81.00, for a total transaction of $279,369.00. Following the sale, the vice president now directly owns 33,715 shares of the company’s stock, valued at approximately $2,730,915. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Christine Houston sold 10,104 shares of Express Scripts stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $70.08, for a total transaction of $708,088.32. Following the sale, the vice president now directly owns 87,400 shares in the company, valued at $6,124,992. The disclosure for this sale can be found here. Insiders have sold a total of 17,001 shares of company stock worth $1,249,505 over the last ninety days. 0.68% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Van ECK Associates Corp grew its holdings in Express Scripts by 5.1% during the 3rd quarter. Van ECK Associates Corp now owns 506,511 shares of the company’s stock worth $32,072,000 after acquiring an additional 24,728 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Express Scripts by 12.5% during the 3rd quarter. Victory Capital Management Inc. now owns 35,421 shares of the company’s stock worth $2,243,000 after acquiring an additional 3,940 shares during the last quarter. Hendershot Investments Inc. bought a new stake in Express Scripts during the 3rd quarter worth approximately $5,132,000. Crossmark Global Holdings Inc. bought a new stake in Express Scripts during the 3rd quarter worth approximately $3,708,000. Finally, LMR Partners LLP bought a new stake in Express Scripts during the 3rd quarter worth approximately $3,230,000. 86.45% of the stock is currently owned by institutional investors.
Express Scripts (NASDAQ ESRX) traded down $0.22 during midday trading on Thursday, hitting $75.83. 3,093,900 shares of the stock were exchanged, compared to its average volume of 4,177,839. The company has a current ratio of 0.73, a quick ratio of 0.61 and a debt-to-equity ratio of 0.86. The firm has a market cap of $43,072.67, a PE ratio of 12.49, a PEG ratio of 0.81 and a beta of 0.93. Express Scripts has a one year low of $55.80 and a one year high of $83.49.
Express Scripts announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 18th that authorizes the company to buyback 45,000,000 outstanding shares. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s management believes its stock is undervalued.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/22/analysts-anticipate-express-scripts-holding-esrx-will-post-earnings-of-2-09-per-share.html.
Express Scripts Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Get a free copy of the Zacks research report on Express Scripts (ESRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.